Fingerprint
Dive into the research topics of 'Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study
Richard S. Finn, Carmelo Bengala, Nuhad Ibrahim, Henri Roche, Joseph Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy, Lori J. Goldstein
Research output: Contribution to journal › Article › peer-review
175
Scopus
citations